Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma

dc.contributor.author	Tatagiba, Marcos
dc.date.accessioned	2020-11-03T12:16:41Z
dc.date.available	2020-11-03T12:16:41Z
dc.date.issued	2020
dc.identifier.issn	1432-1335
dc.identifier.uri	http://hdl.handle.net/10900/109251
dc.language.iso	en	de_DE
dc.publisher	Springer	de_DE
dc.relation.uri	http://dx.doi.org/10.1007/s00432-019-03086-9	de_DE
dc.subject.ddc	610	de_DE
dc.title	Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma	de_DE
dc.type	Article	de_DE
utue.kommentar.intern	online first 2019	de_DE
utue.quellen.id	20200715072417_02385
utue.publikation.seiten	659-670	de_DE
utue.personen.roh	Seystahl, Katharina
utue.personen.roh	Hentschel, Bettina
utue.personen.roh	Loew, Sarah
utue.personen.roh	Gramatzki, Dorothee
utue.personen.roh	Felsberg, Joerg
utue.personen.roh	Herrlinger, Ulrich
utue.personen.roh	Westphal, Manfred
utue.personen.roh	Schackert, Gabriele
utue.personen.roh	Thon, Niklas
utue.personen.roh	Tatagiba, Marcos
utue.personen.roh	Pietsch, Torsten
utue.personen.roh	Reifenberger, Guido
utue.personen.roh	Loeffler, Markus
utue.personen.roh	Wick, Wolfgang
utue.personen.roh	Weller, Michael
dcterms.isPartOf.ZSTitelID	Journal of Cancer Research and Clinical Oncology	de_DE
dcterms.isPartOf.ZS-Volume	146	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE

Files in this item

Files	Size	Format	View
There are no files associated with this item.